Evaluation of Transduction Efficiency in Macrophage Colony-stimulating Factor Differentiated Human Macrophages Using HIV-1 Based Lentiviral Vectors

Overview

Journal BMC Biotechnol

Publisher Biomed Central

Specialty Biotechnology

Date 2011 Feb 2

PMID 21281514

Citations 9

Authors

Francisco J Leyva

Joshua J Anzinger

J Philip McCoy Jr

Howard S Kruth

Affiliations

Soon will be listed here.

Abstract

Background: Monocyte-derived macrophages contribute to atherosclerotic plaque formation. Therefore, manipulating macrophage function could have significant therapeutic value. The objective of this study was to determine transduction efficiency of two HIV-based lentiviral vector configurations as delivery systems for the transduction of primary human blood monocyte-derived macrophages.

Results: Human blood monocytes were transduced using two VSV-G pseudotyped HIV-1 based lentiviral vectors containing EGFP expression driven by either native HIV-LTR (VRX494) or EF1α promoters (VRX1090). Lentiviral vectors were added to cultured macrophages at different times and multiplicities of infection (MOI). Transduction efficiency was assessed using fluorescence microscopy and flow cytometry. Macrophages transduced between 2 and 120 hours after culturing showed the highest transduction efficiency at 2-hours transduction time. Subsequently, cells were transduced 2 hours after culturing at various vector concentrations (MOIs of 5, 10, 25 and 50) to determine the amount of lentiviral vector particles required to maximally transduce human monocyte-derived macrophages. On day 7, all transduced cultures showed EGFP-positive cells by microscopy. Flow cytometric analysis showed with all MOIs a peak shift corresponding to the presence of EGFP-positive cells. For VRX494, transduction efficiency was maximal at an MOI of 25 to 50 and ranged between 58 and 67%. For VRX1090, transduction efficiency was maximal at an MOI of 10 and ranged between 80 and 90%. Thus, transductions performed with VRX1090 showed a higher number of EGFP-positive cells than VRX494.

Conclusions: This report shows that VSV-G pseudotyped HIV-based lentiviral vectors can efficiently transduce human blood monocyte-derived macrophages early during differentiation using low particle numbers that do not interfere with differentiation of monocytes into macrophages.

Citing Articles

Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers.

Chupradit K, Muneekaew S, Wattanapanitch M Cancer Immunol Immunother. 2024; 73(9):170.

PMID: 38954079 PMC: 11219683. DOI: 10.1007/s00262-024-03759-6.

Long-term in vitro monitoring of AAV-transduction efficiencies in real-time with Hoechst 33342.

Hu X, Meister R, Tode J, Framme C, Fuchs H PLoS One. 2024; 19(3):e0298173.

PMID: 38427668 PMC: 10906819. DOI: 10.1371/journal.pone.0298173.

Optimized Nonviral Gene Disruption in Primary Murine and Human Myeloid Cells.

Freund E, Haag S, Haley B, Murthy A Methods Mol Biol. 2023; 2618:201-217.

PMID: 36905519 DOI: 10.1007/978-1-0716-2938-3_15.

High-Yield Human Induced Pluripotent Stem Cell-Derived Monocytes and Macrophages Are Functionally Comparable With Primary Cells.

Cui D, Franz A, Fillon S, Jannetti L, Isambert T, Fundel-Clemens K Front Cell Dev Biol. 2021; 9:656867.

PMID: 33937256 PMC: 8080307. DOI: 10.3389/fcell.2021.656867.

Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9.

Freund E, Lock J, Oh J, Maculins T, Delamarre L, Bohlen C J Exp Med. 2020; 217(7).

PMID: 32357367 PMC: 7336301. DOI: 10.1084/jem.20191692.

References

Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T . Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med. 2004; 6(9):963-73. DOI: 10.1002/jgm.593. View

Ravot E, Comolli G, Lori F, Lisziewicz J . High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment. J Gene Med. 2002; 4(2):161-9. DOI: 10.1002/jgm.256. View

Burke B . Macrophages as novel cellular vehicles for gene therapy. Expert Opin Biol Ther. 2003; 3(6):919-24. DOI: 10.1517/14712598.3.6.919. View

Kruth H . Lipoprotein cholesterol and atherosclerosis. Curr Mol Med. 2002; 1(6):633-53. DOI: 10.2174/1566524013363212. View

Quinn K, Brindley M, Weller M, Kaludov N, Kondratowicz A, Hunt C . Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. J Virol. 2009; 83(19):10176-86. PMC: 2747995. DOI: 10.1128/JVI.00422-09. View

Schneider S, Rusconi S, Seger R, Hossle J . Adenovirus-mediated gene transfer into monocyte-derived macrophages of patients with X-linked chronic granulomatous disease: ex vivo correction of deficient respiratory burst. Gene Ther. 1997; 4(6):524-32. DOI: 10.1038/sj.gt.3300432. View

Kruth H, Jones N, Huang W, Zhao B, Ishii I, Chang J . Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J Biol Chem. 2004; 280(3):2352-60. DOI: 10.1074/jbc.M407167200. View

Neil S, Martin F, Ikeda Y, Collins M . Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol. 2001; 75(12):5448-56. PMC: 114256. DOI: 10.1128/JVI.75.12.5448-5456.2001. View

Huang S, Endo R, Nemerow G . Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol. 1995; 69(4):2257-63. PMC: 188895. DOI: 10.1128/JVI.69.4.2257-2263.1995. View

10.

Waldo S, Li Y, Buono C, Zhao B, Billings E, Chang J . Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol. 2008; 172(4):1112-26. PMC: 2276432. DOI: 10.2353/ajpath.2008.070513. View

11.

Lu Y, Liu C, Zeng L, Lin Z, Dewhurst S, Gartner S . Efficient gene transfer into human monocyte-derived macrophages using defective lentiviral vectors. Cell Mol Biol (Noisy-le-grand). 2003; 49(7):1151-6. View

12.

Carter G, Bernstone L, Baskaran D, James W . HIV-1 infects macrophages by exploiting an endocytic route dependent on dynamin, Rac1 and Pak1. Virology. 2010; 409(2):234-50. DOI: 10.1016/j.virol.2010.10.018. View

13.

Wu X, Wakefield J, Liu H, Xiao H, Kralovics R, Prchal J . Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther. 2000; 2(1):47-55. DOI: 10.1006/mthe.2000.0095. View

14.

Wang G, Levine B, Binder G, Berry C, Malani N, McGarrity G . Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther. 2009; 17(5):844-50. PMC: 2835137. DOI: 10.1038/mt.2009.16. View

15.

De S, Venkateshan C, Seth P, Gajdusek D, GIBBS C . Adenovirus-mediated human immunodeficiency virus-1 Nef expression in human monocytes/macrophages and effect of Nef on downmodulation of Fcgamma receptors and expression of monokines. Blood. 1998; 91(6):2108-17. View

16.

Corbeau P, Kraus G, Wong-Staal F . Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system. Gene Ther. 1998; 5(1):99-104. DOI: 10.1038/sj.gt.3300563. View

17.

Heron M, Hoyert D, Murphy S, Xu J, Kochanek K, Tejada-Vera B . Deaths: final data for 2006. Natl Vital Stat Rep. 2009; 57(14):1-134. View

18.

Miyake K, Suzuki N, Matsuoka H, Tohyama T, Shimada T . Stable integration of human immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells. Hum Gene Ther. 1998; 9(4):467-75. DOI: 10.1089/hum.1998.9.4-467. View

19.

Yee J, Friedmann T, Burns J . Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 1994; 43 Pt A:99-112. DOI: 10.1016/s0091-679x(08)60600-7. View

20.

Schroers R, Sinha I, Segall H, Schmidt-Wolf I, Rooney C, Brenner M . Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther. 2000; 1(2):171-9. DOI: 10.1006/mthe.2000.0027. View